Eirin A, Thaler R, Glasstetter LM, Xing L, Zhu X-Y, Osborne AC, et al. Obesity-driven mitochondrial dysfunction in human adipose tissue-derived mesenchymal stem/stromal cells involves epigenetic changes. Cell Death Dis. 2024;15:387.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barbhuiya PA, Sen S, Pathak MP. Ameliorative role of bioactive phytoconstituents targeting obesity associated NAFLD by modulation of inflammation and lipogenesis pathways: a comprehensive review. Phytochem Rev [Internet]. 2023 [cited 2024 Feb 7]; Available from: https://link.springer.com/https://doi.org/10.1007/s11101-023-09912-w

Pathak MP, Patowary P, Chattopadhyay P, Barbhuiyan PA, Islam J, Gogoi J, et al. Obesity-associated Airway Hyperresponsiveness: Mechanisms Underlying Inflammatory Markers and Possible Pharmacological Interventions. Endocr Metab Immune Disord - Drug Targets [Internet]. 2023 [cited 2023 Nov 27];24. Available from: https://www.eurekaselect.com/223503/article

Putra IGNE, Daly M, Sutin A, Steptoe A, Scholes S, Robinson E. Obesity, psychological well-being related measures, and risk of seven non-communicable diseases: evidence from longitudinal studies of UK and US older adults. Int J Obes [Internet]. 2024 [cited 2024 Jun 3]; Available from: https://www.nature.com/articles/s41366-024-01551-1

Li L, Liu D-W, Yan H-Y, Wang Z-Y, Zhao S-H, Wang B. Obesity is an independent risk factor for non-alcoholic fatty liver disease: evidence from a meta-analysis of 21 cohort studies: Obesity and non-alcoholic fatty liver disease. Obes Rev. 2016;17:510–9.

Article  CAS  PubMed  Google Scholar 

Polyzos SA, Kountouras J, Mantzoros CS. Adipose tissue, obesity and non-alcoholic fatty liver disease. Minerva Endocrinol [Internet]. 2017 [cited 2023 Jul 5];42. Available from: https://www.minervamedica.it/index2.php?show=R07Y2017N02A0092

Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73:202–9.

Article  PubMed  Google Scholar 

Eslam M, Sarin SK, Wong VW-S, Fan J-G, Kawaguchi T, Ahn SH, et al. The Asian pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14:889–919.

Article  PubMed  Google Scholar 

Kaya E, Yilmaz Y. Metabolic-associated fatty liver disease (MAFLD): A multi-systemic disease beyond the liver. J Clin Transl Hepatol. 2022;10:329–38.

Article  PubMed  Google Scholar 

Zhou X-D, Targher G, Byrne CD, Somers V, Kim SU, Chahal CAA, et al. An international multidisciplinary consensus statement on MAFLD and the risk of CVD. Hepatol Int. 2023;17:773–91.

Article  PubMed  Google Scholar 

Guo X, Yin X, Liu Z, Wang J. Non-alcoholic fatty liver disease (NAFLD) pathogenesis and natural products for prevention and treatment. Int J Mol Sci. 2022;23:15489.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barbhuiya PA, Ahmed A, Dutta PP, Sen S, Pathak MP. Mitigating metabolic dysfunction-associated steatotic liver disease (MASLD): The role of bioactive phytoconstituents in Indian culinary spices. Curr Nutr Rep. 2025;14:20.

Article  PubMed  Google Scholar 

Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Ann Hepatol. 2024;29:101133.

Article  PubMed  Google Scholar 

Song SJ, Lai JCT, Wong GLH, Wong VWS, Yip TCF. Can we use old NAFLD data under the new MASLD definition? J Hepatol. 2024;80:e54-6.

Article  PubMed  Google Scholar 

Song R, Li Z, Zhang Y, Tan J, Chen Z. Comparison of NAFLD, MAFLD and MASLD characteristics and mortality outcomes in United States adults. Liver Int. 2024;44:1051–60.

Article  CAS  PubMed  Google Scholar 

Hagström H, Vessby J, Ekstedt M, Shang Y. 99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical. J Hepatol. 2024;80:e76–7.

Article  PubMed  Google Scholar 

Younossi ZM, Paik JM, Stepanova M, Ong J, Alqahtani S, Henry L. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease. J Hepatol. 2024;80:694–701.

Article  CAS  PubMed  Google Scholar 

Long J, Xu Y, Zhang X, Wu B, Wang C. Role of FXR in the development of NAFLD and intervention strategies of small molecules. Arch Biochem Biophys. 2024;757:110024.

Article  CAS  PubMed  Google Scholar 

Lindenmeyer CC, McCullough AJ. The natural history of nonalcoholic fatty liver disease-an evolving view. Clin Liver Dis. 2018;22:11–21.

Article  PubMed  PubMed Central  Google Scholar 

Ahmed MH, Byrne CD. Modulation of sterol regulatory element binding proteins (SREBPs) as potential treatments for non-alcoholic fatty liver disease (NAFLD). Drug Discov Today. 2007;12:740–7.

Article  CAS  PubMed  Google Scholar 

Gong Z, Han S, Li C, Meng T, Huo Y, Liu X, et al. Rhinacanthin C ameliorates insulin resistance and lipid accumulation in NAFLD mice via the AMPK/SIRT1 and SREBP-1c/FAS/ACC signaling pathways. Evid-Based Complement Altern Med ECAM. 2023;2023:6603522.

Article  Google Scholar 

Ni X, Wang H. Silymarin attenuated hepatic steatosis through regulation of lipid metabolism and oxidative stress in a mouse model of nonalcoholic fatty liver disease (NAFLD). Am J Transl Res. 2016;8:1073–81.

CAS  PubMed  PubMed Central  Google Scholar 

Andrade JMO, Paraíso AF, De Oliveira MVM, Martins AME, Neto JF, Guimarães ALS, et al. Resveratrol attenuates hepatic steatosis in high-fat fed mice by decreasing lipogenesis and inflammation. Nutrition. 2014;30:915–9.

Article  CAS  PubMed  Google Scholar 

Zhao L, Yang L, Ahmad K. Kaempferol ameliorates palmitate-induced lipid accumulation in HepG2 cells through activation of the Nrf2 signaling pathway. Hum Exp Toxicol. 2023;42:096032712211467.

Article  Google Scholar 

Pisonero-Vaquero S, Martínez-Ferreras Á, García-Mediavilla MV, Martínez-Flórez S, Fernández A, Benet M, et al. Quercetin ameliorates dysregulation of lipid metabolism genes via the PI3K/AKT pathway in a diet-induced mouse model of nonalcoholic fatty liver disease. Mol Nutr Food Res. 2015;59:879–93.

Article  CAS  PubMed  Google Scholar 

Jo HK, Kim GW, Jeong KJ, Kim DY, Chung SH. Eugenol ameliorates hepatic steatosis and fibrosis by down-regulating SREBP1 gene expression via AMPK-mTOR-p70S6K signaling pathway. Biol Pharm Bull. 2014;37:1341–51.

Article  CAS  PubMed  Google Scholar 

Um MY, Hwang KH, Ahn J, Ha TY. Curcumin attenuates diet-induced hepatic steatosis by activating amp -activated protein kinase. Basic Clin Pharmacol Toxicol. 2013;113:152–7.

Article  CAS  PubMed  Google Scholar 

Lu J, Cheng B, Fang B, Meng Z, Zheng Y, Tian X, et al. Protective effects of allicin on 1,3-DCP-induced lipid metabolism disorder in HepG2 cells. Biomed Pharmacother Biomedecine Pharmacother. 2017;96:1411–7.

Article  CAS  Google Scholar 

Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell. 1997;89:331–40.

Article  CAS  PubMed  Google Scholar 

Goldstein JL, DeBose-Boyd RA, Brown MS. Protein sensors for membrane sterols. Cell. 2006;124:35–46.

Article  CAS  PubMed  Google Scholar 

Sato R. Sterol metabolism and SREBP activation. Arch Biochem Biophys. 2010;501:177–81.

Article  CAS  PubMed  Google Scholar 

Jeon T-I, Osborne TF. SREBPs: metabolic integrators in physiology and metabolism. Trends Endocrinol Metab TEM. 2012;23:65–72.

Article  CAS  PubMed  Google Scholar 

Rong S, Cortés VA, Rashid S, Anderson NN, McDonald JG, Liang G, et al. Expression of SREBP-1c Requires SREBP-2-mediated Generation of a Sterol Ligand for LXR in Livers of Mice. eLife. 2017;6:e25015.

Article  PubMed  PubMed Central  Google Scholar 

Shimano H, Sato R. SREBP-regulated lipid metabolism: convergent physiology - divergent pathophysiology. Nat Rev Endocrinol. 2017;13:710–30.

Article  CAS  PubMed  Google Scholar 

Ang MJ, Moon C. SREBP and central nervous system disorders: genetic overlaps revealed by in silico analysis. J Integr Neurosci. 2022;21:95.

Article  PubMed